Abstract and Introduction
Invasive fungal infections due to Candida are the third most common late-onset infection in infants born with birth weight <1500 g. Invasive candidiasis in infants born with birth weight <1000 g is associated with a 30% mortality and with neurodevelopmental impairment in more than half the survivors. A high degree of suspicion and a thorough multisystem evaluation is necessary for diagnosis of invasive fungal infections and to detect complications or sequalae. Amphotericin B deoxycholate is the mainstay in the treatment of invasive fungal infections in newborns. Early initiation of enteral feeds with human milk, decreasing dependence on catheters and avoidance of antacids, steroids and broad-spectrum antibiotics are the recommended preventive measures. Fluconazole prophylaxis should be targeted towards neonates born with <1000 g in neonatal units where baseline rates of invasive candidiasis are more than 5%.
Invasive fungal infections due to Candida are the third most common late-onset infections (>72 h of age) in very low birth weight (VLBW) infants (birth weight <1500 g). Invasive Candida infections, in extremely low birth weight (ELBW) infants (birth weight <1000 g) is associated with a mortality of approximately 30% and adverse neurodevelopmental outcomes in half of the survivors.[1,2] Since Candida is the major fungal species isolated from neonates with fungal infection, the majority of this review will focus on neonatal Candida infections.
Expert Rev Anti Infect Ther. 2013;11(7):709-721. © 2013 Expert Reviews Ltd.